Baxter International (NYSE: BAX) reported earnings on Jan. 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Baxter International met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded slightly, and GAAP earnings per share expanded significantly.
Gross margins contracted, operating margins dropped, net margins increased.
Revenue details
Baxter International recorded revenue of $3.59 billion. The 15 analysts polled by S&P Capital IQ expected to see revenue of $3.57 billion. Sales were 2.7% higher than the prior-year quarter's $3.50 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS details
Non-GAAP EPS came in at $1.17. The 20 earnings estimates compiled by S&P Capital IQ predicted $1.17 per share on the same basis. GAAP EPS of $1.01 for Q4 were 14% higher than the prior-year quarter's $0.72 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 49.1%, 90 basis points worse than the prior-year quarter. Operating margin was 17.4%, 590 basis points worse than the prior-year quarter. Net margin was 12.9%, 80 basis points better than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $3.30 billion. On the bottom line, the average EPS estimate is $1.00.
Next year's average estimate for revenue is $14.19 billion. The average EPS estimate is $4.55.
Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Baxter International is outperform, with an average price target of $63.00.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Baxter International the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Baxter International to My Watchlist.
